Detail akcie Defence Rg-A-Reg S online

Business Summary: Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.
Financial Summary: BRIEF: For the three months ended 30 September 2025, Defence Therapeutics Inc revenues was not reported. Net loss increased 16% to C$703K. Higher net loss reflects Investor relations and shareholder commu increase from C$59K to C$147K (expense), Share-based compensation increase of 62% to C$114K (expense), Accounting and legal increase from C$16K to C$50K (expense).